Methods
Aggregated clinician-level claims data were obtained from the Centers for Medicare & Medicaid Services Medicare Part B Physician/Supplier Procedure Summary Master Files from 2007 to 2015. 16, 17 These files contain all Medicare Part B fee-forservice billing claims that were submitted and paid, as sorted by clinician specialty and Healthcare Common Procedure Coding System (HCPCS) codes, including those for the destruction of premalignant lesions of the skin (equivalent to Current Procedural Terminology codes 17 000-17 004). 18 Because the cost of AK treatment is based on the number of AK lesions destroyed, the prevalence of AK was estimated conservatively by the sum of (HCPCS 17 000 claims + 17 003 claims) + (15 × 17 004 claims). Treatment use rates per 1000 Medicare Part B fee-for-service beneficiaries were normalized by published annual enrollment numbers. Analysis was stratified by specialty to determine market share among dermatologists, all other physicians, and independently billing nonphysician clinicians (NPCs) (including physician assistants and nurse practitioners 
Results

Number of AK Lesions Treated and Billing Claims by Specialty
More than 35.6 million AK lesions were treated in 2015, increasing from 29.7 million in 2007. In contrast, the estimated number of Medicare Part B fee-for-service enrollees increased modestly, from 32. 
Key Points
Question How is the use and cost of actinic keratosis destruction changing in the aging population?
Findings This billing claims analysis found that, in the Medicare Part B fee-for-service population, the estimated number of actinic keratosis lesions treated per 1000 beneficiaries increased from 917 in 2007 to 1051 in 2015, while mean inflation-adjusted payments decreased from $11 749 to $10 942 per 1000 beneficiaries owing to successive reimbursement cuts. In 2015, a total of 13.5% of actinic keratosis lesions were treated by independently billing nurse practitioners and physician assistants.
Meaning Actinic keratosis appears to impose high and increasing levels of treatment burden in the aging population. Prior health economics studies showed that insured patients' demand for health care is inelastic to price changes but, rather, reflects overall access to care. 24,25 Financial incentives have little effect on clinician choices when treatment is considered nondiscretionary. 26 In the absence of prognostic markers for the malignancy potential of specific AK lesions, identified AK lesions are deemed to require treatment despite low individual risks for malignant transformation and known potential for regression. 27,28 Patient-level and clinician-level differences in deciding whether to treat, how to treat, how often to treat, and how many AK lesions to treat-as well as access to dermatologic care overall from dermatologists or NPCs-may account for significant variations in cost and use of lesion-directed AK management.
14,29
Increases of AK lesion-directed destructive procedures were accompanied by concurrent increases in AK field treatments and skin cancer diagnostic and treatment procedures. these prior studies, our data provided additional ecologic evidence to suggest the increasing treatment use and cost burden of AK and keratinocyte carcinomas in the United States.
In the current era of value-based care, 33 rising use of AK treatment with unexplained variations in management call for innovations to measure and improve value and patient centeredness in AK treatment and prevention of keratinocyte carcinoma. Application of the chronic care model to manage AK and keratinocyte carcinomas is proposed to coordinate care delivery, which may enable field-directed therapies for high-risk patients with severe actinic burden or a history of multiple keratinocyte carcinomas. 34 Clinical decision aids can guide treatment selection by aligning patients' and physicians' understanding of AK, providing individualized prognostic information, and incorporating patients' personal values and preferences about treatment benefits, risks, and costs. 35, 36 Research should address the cost-effectiveness of AK surveillance and treatment strategies and optimize their intensity and frequency. 37, 38 Evidence-based clinical practice guidelines on AK management will be necessary for developing and disseminating high-value pathways of care for AK. 39, 40 Since management of AK has accounted for more than 14% of US dermatologist visits, 41 optimization of AK care delivery has the potential of improving critical access to medical dermatology care. Rigorous natural history data are critically needed to define the clinical characteristics of AKs with a higher likelihood of transformation into invasive squamous cell carcinoma. Growth in AK destructive procedures is partly attributable to increases in treatment access from independently billing NPCs, who treated 13.5% of AK lesions in 2015. An influx of NPCs in dermatology was fueled by continued shortage in dermatologist supply, increasing training and supply of NPCs, lower salary costs for NPCs, and expansion of NPCs' scope of practice. 42, 43 Dermatologists were affiliated with 92% of independently billing NPCs who perform dermatologic procedures, 44 but physician supervision may vary. 42 News media highlighted concerns of adequate NPC supervision with anecdotes of excessively high volume of AK treatment. 45 One study suggested that NPCs may have lower accuracy in skin cancer diagnosis compared with attending dermatologists, but the comparison was not statistically significant. 46 Future research should balance improving access to and value of AK treatment in the context of expanding NPC involvement in care delivery.
Limitations
Our data pertain only to AK-related procedures in Medicare Part B fee-for-service beneficiaries and could not capture claims 
Conclusions
Actinic keratosis imposes continuously increasing levels of treatment burden in the Medicare fee-for-service population. Reimbursement cuts have been used to control rising costs of AK treatment. Critical research is warranted to optimize access to AK treatment and value for prevention of keratinocyte carcinoma.
